Colorectal Cancer

Christina Wu, MB, BCh, MD, shares the study design and efficacy data of the MOUNTAINEER-01 study, which explored combination tucatinib plus trastuzumab for the treatment of patients with HER2+ metastatic colorectal cancer.

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.

Daniel Walden, MD, presents the scenario of a 65-year-old man diagnosed with HER2+ metastatic colorectal cancer to the expert panel for discussion.

Experts emphasize the importance of acquiring both tissue and circulating tumor DNA (ctDNA) for molecular testing in patients with metastatic colorectal cancer, address challenges such as lack of tissue and costs, and highlight the role of HER2 as a biomarker.

Daniel Ahn, DO, discusses the evolution of biomarker testing in metastatic colorectal cancer, highlighting the shift from understanding only the prognostic implications of genetic alterations to recognizing their predictive role in targeted therapies, and emphasizes the potential of circulating tumor DNA for rapid diagnosis and assessing treatment response.

Tanios Bekaii-Saab, MD, and colleagues address updates in metastatic colorectal cancer treatment, highlighting its prevalence in the U.S., the concerning rise in younger patients, and the ongoing uncertainty regarding the causes of this trend, with potential factors like environment and microbiome under investigation.

The FDA okayed 2 breakthrough therapy designations for fam-trastuzumab deruxtecan-nxki in HER2-positive solid tumors and colorectal cancer, which are based on data from the phase 2 DESTINY-PanTumor02 and DESTINY-CRC02 trials.

Results from a randomized trial suggest that neoadjuvant FOLFOX may be an effective treatment for patients with locally advanced rectal cancer who are suitable to undergo sphincter-sparing surgery.

Prospective, real-world data indicate that most patients with colon or rectal cancer who undergo surgery remain independent.

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.

Specialists on colorectal cancer discuss the effect of MRD on monitoring strategies and adjuvant therapy decisions for patients with colorectal cancer.

An overview colorectal cancer clinical trials studying early intervention based on MRD positivity.

Results from the phase 3 SUNLIGHT trial support the approval of trifluridine/tipiracil plus bevacizumab in patients with previously treated, metastatic colorectal cancer.

Aparna Parikh, MD, MS, talks about the MD Anderson INTERCEPT program, which is studying the relationship between ctDNA and recurrence in colorectal cancer.

Daniel H. Ahn, DO, discusses the CIRCULATE-Japan trial, which is studying how ctDNA can be used to guide adjuvant therapy in colorectal cancer.

The panel compares cfDNA with ctDNA for assessing MRD, and outlines when ctDNA testing is ordered and how it’s collected.

Joleen Hubbard, MD, compares CEA with ctDNA for monitoring patients with colorectal cancer.

Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.

A comprehensive discussion on treatment decision-making for patients with colorectal cancer following the IDEA collaboration analysis.

Findings from the phase 3 FRESCO-2 trial support fruquintinib plus best supportive care as a global treatment option for patients with refractory metastatic colorectal cancer.

The expert panel discusses how MRD positivity affects treatment decisions for patients with colorectal cancer.

Experts on colorectal cancer present a patient case, offer their initial impressions, and discuss disease staging.

The agent appears to be less effective among patients with HER2-low disease, according to final results from the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.

An expert panel reviews the management of toxicities, genetic testing, and other topics in colorectal cancer.

The FDA’s approval of the FoundationOne Liquid CDx as a companion diagnostic may improve access to treatment with encorafenib plus cetuximab for patients with metastatic colorectal cancer harboring a BRAF V600E alteration.

Fruquintinib plus best supportive care elicits a progression-free survival benefit across all prior treatment subgroups among patients with refractory metastatic colorectal cancer in the phase 3 FRESCO-2 trial.

Among patients with colorectal cancer who are ineligible for intensive chemotherapy, trifluridine/tipiracil plus bevacizumab yielded similar survival outcomes compared with capecitabine plus bevacizumab.

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.